Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,590 questions in 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer
current versionsNo studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Dactolisib (1 RCT; 62 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | HR 0.55 [0.25, 1.21] | 1 study · 62 participants | Low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo SSA (3 RCTs; 586 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | HR 0.51 [0.34, 0.77] | 3 studies · 586 participants | Moderate |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Placebo (4 RCTs; 844 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | no estimate extracted | 4 studies · 844 participants | Ungraded |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Total studies: 11 Total participants: 1338 Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | no estimate extracted | 11 participants | Ungraded |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Bevacizumab + SSA (1 RCT; 44 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | OR 45 [3.32, 609] | 1 study · 44 participants | Very low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo 177‐Lu‐DOTATATE + SSA (1 RCT; 229 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | OR 30.4 [8.19, 113] | 1 study · 177 participants | Very low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Everolimus + SSA (1 RCT; 39 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | OR 15.1 [2.55, 88.9] | 1 study · 39 participants | Very low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Interferon + SSA (4 RCTs; 283 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | OR 5.71 [1.9, 17.2] | 4 studies · 283 participants | Very low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Interferon (2 RCTs; 86 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | OR 4.03 [0.86, 18.8] | 2 studies · 86 participants | Very low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Surufatinib (1 RCT; 198 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | OR 3.5 [1.21, 10.1] | 1 study · 198 participants | Moderate |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Everolimus + SSA (2 RCTs; 589 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | OR 2.89 [1.61, 5.19] | 2 studies · 589 participants | Moderate |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo SSA (7 RCTs; 796 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | OR 2.93 [1.36, 6.32] | 7 studies · 796 participants | Moderate |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Everolimus (1 RCT; 302 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | OR 2.53 [0.95, 6.79] | 1 study · 302 participants | Very low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Placebo (4 RCT; 789 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | no estimate extracted | 4 studies · 789 participants | Ungraded |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Streptozocin + 5‐FU (1 RCT; 20 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | OR 0.13 [0, 4.58] | 1 study · 5 participants | Very low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Total studies: 9 Total participants: 1311Â Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | no estimate extracted | 9 participants | Ungraded |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo 177‐Lu‐DOTATATE + SSA (1 RCT; 229 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | HR 0.07 [0.02, 0.26] | 1 study · 177 participants | Very low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Everolimus + SSA (1 RCT; 39 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | HR 0.12 [0.03, 0.54] | 1 study · 39 participants | Very low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Bevacizumab + SSA (2 RCTs; 446 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | HR 0.18 [0.04, 0.94] | 2 studies · 446 participants | Very low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Interferon + SSA (3 RCTs; 512 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | HR 0.23 [0.06, 0.93] | 3 studies · 512 participants | Very low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Interferon (1 RCT; 66 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | HR 0.27 [0.07, 1.1] | 1 study · 66 participants | Very low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Interferon + SSA (2 RCTs; 171 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | OR 2.88 [1.16, 7.13] | 2 studies · 171 participants | Very low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Surufatinib (1 RCT; 198 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | HR 0.33 [0.12, 0.88] | 1 study · 198 participants | Moderate |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo SSA (5 RCTs; 492 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | HR 0.34 [0.16, 0.76] | 5 studies · 492 participants | High |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Everolimus (1 RCT; 175 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | HR 0.56 [0.21, 1.49] | 1 study · 175 participants | Low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Placebo (4 RCTs; 531 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | no estimate extracted | 4 studies · 531 participants | Ungraded |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Interferon (1 RCT; 66 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | OR 2.58 [0.75, 8.81] | 1 study · 66 participants | Very low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo SSA (4 RCTs, 804 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | OR 2.36 [1.43, 3.88] | 4 studies · 804 participants | Moderate |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Surufatinib (1 RCT; 172 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | OR 1.99 [1.02, 3.88] | 1 study · 172 participants | High |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Sunitinib (1 RCT; 171 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | OR 1.72 [0.91, 3.27] | 1 study · 171 participants | Low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Placebo (4 RCTs; 957 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | no estimate extracted | 4 studies · 957 participants | Ungraded |
Aspirin (ASA) vs vitamin K antagonist (VKA) All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents: 6 months follow‐up Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 3 [0.12, 73.24] | 1 study · 440 participants | Very low |
Aspirin (ASA) vs vitamin K antagonist (VKA) Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs low molecular weight heparin (LMWH) All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 1 [0.06, 15.81] | 2 studies · 781 participants | Very low |
Aspirin (ASA) vs low molecular weight heparin (LMWH) Symptomatic deep vein thrombosis · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 1.23 [0.49, 3.08] | 2 studies · 781 participants | Very low |
Aspirin (ASA) vs low molecular weight heparin (LMWH) Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 7.71 [0.97, 61.44] | 2 studies · 781 participants | Very low |
Aspirin (ASA) vs low molecular weight heparin (LMWH) Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 6.97 [0.36, 134.11] | 2 studies · 781 participants | Very low |
Aspirin (ASA) vs low molecular weight heparin (LMWH) Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 1.42 [0.35, 5.78] | 2 studies · 781 participants | Very low |
Aspirin (ASA) vs low molecular weight heparin (LMWH) All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 1 [0.06, 15.89] | 1 study · 440 participants | Very low |
Aspirin (ASA) vs low molecular weight heparin (LMWH) Symptomatic deep vein thrombosis · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 1.2 [0.53, 2.72] | 1 study · 440 participants | Very low |
Aspirin (ASA) vs low molecular weight heparin (LMWH) Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 9 [0.49, 166.17] | 1 study · 440 participants | Very low |
Aspirin (ASA) vs low molecular weight heparin (LMWH) Major bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs vitamin K antagonist (VKA) Symptomatic deep vein thrombosis · ambulatory patients with multiple myeloma receiving immunomodulatory agents: 6 months follow‐up Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 0.57 [0.24, 1.33] | 1 study · 440 participants | Very low |
Aspirin (ASA) vs low molecular weight heparin (LMWH) Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 0.33 [0.01, 8.1] | 1 study · 439 participants | Very low |
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) Symptomatic deep vein thrombosis · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 2.32 [0.91, 5.93] | 1 study · 439 participants | Very low |
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 8.96 [0.49, 165.42] | 1 study · 439 participants | Very low |
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) Major bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 0.33 [0.03, 3.17] | 1 study · 439 participants | Very low |
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 2 [0.18, 21.9] | 1 study · 440 participants | Very low |